In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.
|Webcasts|June 24, 2020
Harnessing CAR-T Therapy for Hematologic Malignancies and Solid Tumors: Experience from City of Hope
In this exclusive webcast, cutting-edge researchers from the Department of Hematology & Hematopoietic Cell Transplantation share their most recent experiences reprogramming T cells with chimeric antigen receptors (CARs) to tackle both hematologic and solid tumors. Live: Wednesday, Jun. 24, 2020 at 12pm EDT | 1pm CDT | 9am PDT On demand available after airing until Jun. 24, 2021. Register free
Register free:
Event Overview:
Cellular therapy promises dramatic advances in oncology, harnessing the immune system itself to fight cancer. And although CAR-T cell therapy has seen most of its success in blood cancers, there is progress and promise on the solid tumor front as well.
In this exclusive webcast, cutting-edge researchers from the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Cancer Center-Elizabeth Budde, MD, PhD and Saul Price, PhD-share their most recent experiences reprogramming T cells with chimeric antigen receptors (CARs) to tackle both hematologic and solid tumors.
They will conclude with a Question & Answer session, moderated by Al Blunt, MD, Senior Vice President, Precision for Medicine.
Key Learning Objectives:
Attendees will get expert insights regarding:
- Overview of adoptive therapy using CAR-engineered T cells, with details on key variables in CAR design, adoptive transfer, and T-cell isolation, activation, and expansion
- Details of T-cell therapy research at City of Hope to treat brain metastases, solid tumors, and hematological cancers
- Future research foci, including reverse translation, overcoming tumor antigen escape, and improving T-cell persistence in challenging tumors
Speakers: Dr. Elizabeth Budde, Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
Dr. Saul Priceman, Ph.D., Assistant Professor, City of Hope
Dr. Al Blunt, MD, Senior VP, Medical – Americas, Precision for Medicine
Time and date: Wednesday, Jun. 24, 2020 at 12pm EDT | 1pm CDT | 9am PDT
On demand available after airing until Jun. 24, 2021.
Sponsor: Precision for Medicine
Register free:
Related to this article
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.
ACT Brief: Community Research Financing Gaps, Neuroscience Endpoint Data, and Teva’s Biosimilar Deal
In today’s ACT Brief, we examine why community research needs lasting financing and infrastructure, how electronic outcome tools can strengthen neuroscience endpoints, and how Teva is licensing two biosimilars from Samsung Bioepis.
Neuroscience trials struggle to show benefit because symptoms are subjective and variable, and eCOA strengthens dossiers by standardizing ClinRO administration, capturing outcomes in real time to reduce recall bias, and adding patient and caregiver perspectives that clinician scales miss.
Community participation gaps look less like a question of patient willingness and more like a financing and infrastructure problem that no single bill has yet solved.
In today’s ACT Brief, we examine what changes when AI is embedded across clinical operations, why faster trial data isn’t yet producing faster decisions, and how FDA granted accelerated approval to a therapy for a rare airway disease.
Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
Trending on Applied Clinical Trials Online
1
Comparing OpenAI and Mistral on Clinical Trial Matching
2
Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health
3
From Complexity to Endpoint Meaningfulness: Addressing Key Neuroscience Trial Challenges with eCOA
4
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
5